Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04729322
Title	Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	M.D. Anderson Cancer Center
Indications	colorectal adenocarcinoma small intestine adenocarcinoma
Therapies	Fecal microbiota + Nivolumab Fecal microbiota + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA